Frequency of anti-nuclear antibodies in multiple sclerosis - PubMed

Comparative Study

Frequency of anti-nuclear antibodies in multiple sclerosis

S Barned et al. Neurology. 1995 Feb.

Abstract

We found anti-nuclear antibodies (ANA) in 26.7% of 150 relapsing-remitting and in 30.4% of 23 chronic progressive definite multiple sclerosis (MS) patients by retrospective chart review. These patients did not have systemic lupus erythematosus. Since ANA are not pathogenically relevant in MS, they are false-positive, and likely reflect systemic immune dysregulation in MS.

Comment in

• Antinuclear antibodies in multiple sclerosis.

  Heinzlef O, Johannet C, Tournier-Lasserve E, Roullet E. Heinzlef O, et al. Neurology. 1995 Dec;45(12):2299-300; author reply 2300-1. doi: 10.1212/wnl.45.12.2299-d. Neurology. 1995. PMID: 8848219 No abstract available.

• Antinuclear antibodies in multiple sclerosis.

  Aisen ML, Aisen PS. Aisen ML, et al. Neurology. 1995 Dec;45(12):2299-300;author reply 2300-1. doi: 10.1212/wnl.45.12.2299-c. Neurology. 1995. PMID: 8848220 No abstract available.

Similar articles

• Frequency and significance of antinuclear antibodies in multiple sclerosis.

  Collard RC, Koehler RP, Mattson DH. Collard RC, et al. Neurology. 1997 Sep;49(3):857-61. doi: 10.1212/wnl.49.3.857. Neurology. 1997. PMID: 9305354

• Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis.

  Fujii T, Yamasaki R, Miyachi Y, Nagata S, Maimaitijiang G, Nakamura Y, Shinoda K, Matsushita T, Isobe N, Kira JI. Fujii T, et al. J Neurol Sci. 2020 Feb 15;409:116619. doi: 10.1016/j.jns.2019.116619. Epub 2019 Dec 6. J Neurol Sci. 2020. PMID: 31835211

• Relevance of antinuclear antibody in diagnosis and characteristics of multiple sclerosis.

  Koshorek J, Hu C, Wang Y, Grkovski R, Lin D, Fitzgerald K, Newsome SD, Mowry EM. Koshorek J, et al. Mult Scler Relat Disord. 2024 Jul;87:105639. doi: 10.1016/j.msard.2024.105639. Epub 2024 May 4. Mult Scler Relat Disord. 2024. PMID: 38704876

• [Antinuclear antibodies in multiple sclerosis].

  Antigüedad A, Ruiz J, Mendibe MM, Zarranz JJ. Antigüedad A, et al. Neurologia. 1997 Jun-Jul;12(6):245-8. Neurologia. 1997. PMID: 9303591 Spanish.

• [Antinuclear antibodies without connective tissue disease : Antibodies against LEDGF/DSF70].

  Mierau R. Mierau R. Z Rheumatol. 2016 May;75(4):372-80. doi: 10.1007/s00393-016-0051-0. Z Rheumatol. 2016. PMID: 26820723 Review. German.

Cited by

• Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack?

  Etemadifar M, Fatemi A, Hashemijazi H, Kazemizadeh A. Etemadifar M, et al. J Res Med Sci. 2013 Jul;18(7):617-20. J Res Med Sci. 2013. PMID: 24516496 Free PMC article.

• The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.

  Hottenrott T, Dersch R, Berger B, Endres D, Huzly D, Thiel J, Rauer S, Stich O, Salzer U, Venhoff N. Hottenrott T, et al. BMC Neurol. 2018 Jan 31;18(1):14. doi: 10.1186/s12883-018-1018-3. BMC Neurol. 2018. PMID: 29386006 Free PMC article.

• Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

  Solomon AJ, Hills W, Chen Z, Rosenbaum J, Bourdette D, Whitham R. Solomon AJ, et al. PLoS One. 2013 Jun 12;8(6):e65385. doi: 10.1371/journal.pone.0065385. Print 2013. PLoS One. 2013. PMID: 23776474 Free PMC article.

• Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis.

  Rakers F, Fritsch A, Herrmann A, Tannapfel A, Schwab M. Rakers F, et al. BMJ Neurol Open. 2023 Sep 6;5(2):e000481. doi: 10.1136/bmjno-2023-000481. eCollection 2023. BMJ Neurol Open. 2023. PMID: 37705760 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information